Zhejiang Hengyan Pharmaceutical Technology

Zhejiang Hengyan Pharmaceutical Technology is a Chinese pharmaceutical research and development company specializing in the development of innovative small molecule drugs and high-quality generic formulations. Based in Zhejiang province, the company maintains a diverse pipeline targeting respiratory, gastrointestinal, and musculoskeletal conditions. Notable achievements include the development and successful technology transfer of Levosalbutamol Hydrochloride to Shandong Xinhua Pharmaceutical and the advancement of HY2233, a novel SIRT1 activator for antispasmodic indications. The company is also active in conducting clinical bioequivalence studies for a range of therapeutic agents, including Vonoprazan Fumarate and Iguratimod, positioning itself as a key player in the Chinese pharmaceutical R&D and licensing landscape.